Cost-effectiveness of drotrecogin alfa (activated) in the treatment of severe sepsis*

This publication has 27 references indexed in Scilit:

• Understanding Costs and Cost-Effectiveness in Critical Care
  American Journal of Respiratory and Critical Care Medicine, 2002
• Epidemiology of severe sepsis in the United States: Analysis of incidence, outcome, and associated costs of care
  Critical Care Medicine, 2001
• Efficacy and Safety of Recombinant Human Activated Protein C for Severe Sepsis
  New England Journal of Medicine, 2001
• Changes of the hemostatic network in critically ill patients-Is there a difference between sepsis, trauma, and neurosurgery patients?
  Critical Care Medicine, 2000
• The Journal's Policy on Cost-Effectiveness Analyses
  New England Journal of Medicine, 1994
• Epidemic Meningococcemia and Purpura Fulminans with Induced Protein C Deficiency
  Clinical Infectious Diseases, 1993
• Time Course of Hemostatic Abnormalities in Sepsis and its Relation to Outcome
  Chest, 1993
• American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference
  Critical Care Medicine, 1992
• Septic Shock, Multiple Organ Failure, and Disseminated Intravascular Coagulation
  Chest, 1992
• The protein C anticoagulant pathway.
  Arteriosclerosis and Thrombosis: A Journal of Vascular Biology, 1992